The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...
No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety ...
A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
What is laser photocoagulation? A laser procedure that seals leaking blood vessels to slow vision loss in wet age-related ...
Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
Outlook Therapeutics (OTLK) stock rises as the company's wet AMD therapy ONS-5010 undergoes FDA review, with a decision ...
The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
In this video, David A. Eichenbaum, MD, FASRS, discusses late-stage wet age-related macular degeneration assets presented at the American Academy of Ophthalmology meeting.Eichenbaum noted that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback